Letter
Bisphosphonates in osteoporosis
Review overemphasises benefits and downplays serious harms
Cite this as:
BMJ
2012;345:e5989
- Vijaya Musini, assistant professor1,
- Barbara Mintzes, assistant professor1,
- Aaron Tejani, researcher, therapeutics initiative1,
- James M Wright, professor1
- 1Departments of Anesthesiology, Pharmacology and Therapeutics, and Medicine, University of British Columbia, BC, Vancouver, Canada V6T 1Z3
- vijaya{at}ti.ubc.ca
We recently conducted a systematic review of bisphosphonates in postmenopausal women with osteoporosis. Our critical appraisal of evidence from 33 randomised controlled trials (25 375 women) of at least one year’s duration reached different conclusions from those of Poole and Compston.1 2
The goal of treatment is prevention of fragility fractures. Effects on bone mineral …
Sign in
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
Social bookmarking